Amygdala and hippocampal substructure volumes and their association with improvement in mood symptoms in patients with mood disorders undergoing electroconvulsive therapy.
Amygdala
Electroconvulsive therapy
Hippocampus
Major depressive disorder;Bipolar disorder
Structural MRI
Journal
Psychiatry research. Neuroimaging
ISSN: 1872-7506
Titre abrégé: Psychiatry Res Neuroimaging
Pays: Netherlands
ID NLM: 101723001
Informations de publication
Date de publication:
06 Jul 2024
06 Jul 2024
Historique:
received:
04
10
2023
revised:
05
07
2024
accepted:
05
07
2024
medline:
11
7
2024
pubmed:
11
7
2024
entrez:
10
7
2024
Statut:
aheadofprint
Résumé
Electroconvulsive therapy (ECT) demonstrates favorable outcomes in the management of severe depressive disorders. ECT has been consistently associated with volumetric increases in the amygdala and hippocampus. However, the underlying mechanisms of these structural changes and their association to clinical improvement remains unclear. In this cross-sectional structural MRI study, we assessed the difference in amygdala subnuclei and hippocampus subfields in n = 37 patients with either unipolar or bipolar disorder immediately after eighth ECT sessions compared to (n = 40) demographically matched patients in partial remission who did not receive ECT (NoECT group). Relative to NoECT, the ECT group showed significantly larger bilateral amygdala volumes post-treatment, with the effect originating from the lateral, basal, and paralaminar nuclei and the left corticoamydaloid transition area. No significant group differences were observed for the hippocampal or cortical volumes. ECT was associated with a significant decrease in depressive symptoms. However, there were no significant correlations between amygdala subnuclei volumes and symptom improvement. Our study corroborates previous reports on increased amygdalae volumes following ECT and further identifies the subnuclei driving this effect. However, the therapeutic effect of ECT does not seem to be directly related to structural changes in the amygdala.
Identifiants
pubmed: 38986265
pii: S0925-4927(24)00082-9
doi: 10.1016/j.pscychresns.2024.111859
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111859Informations de copyright
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest KWM has received consultancy fees from Lundbeck, Janssen, Angelini Pharma and Richter Gedeon in the past three years. JZP has within the last three years received honoraria from Lundbeck Pharma. LVK has within recent three years been a consultant for Lundbeck and Teva A/S. JM, SC, EBKS, ATYN, MBJ report no conflicts of interest.